-
Clinical features and outcomes of adult Langerhans cell histiocytosis: A single-center experience. Int J Hematol. 2020 Jun 8. doi: 10.1007/s12185-020-02892-z.
Kobayashi M, Ando S, kawamata T, Makiyama J, Yokoyama K, Imai Y, Tojo A.
-
The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR-T cells. PLoS One 15(4): e0231896, 2020
Futami M, Suzuki K, Kato S, Tahara Y, Imai Y, Mimura T, Watanabe Y, Tojo A.
-
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): the phase 2, multicenter N-Road study. Cancer Med. 2020 Apr 6. doi: 10.1002/cam4.3034. Online ahead of print
Nishiwaki K, Sugimoto K, Tamaki S, Hisatake J, Yokoyama H, Igarashi T, Shinagawa A, Sugawara A, Yujiri T, Tojo A, Wakita H, and Shimousa Hematology Study Group.
-
Successful clinical sequencing in an elderly patient with refractory Sézary syndrome: a case report. JCO Precision Oncol. 4.534-60, 2020
Hijikata Y, Yokoyama K, Tani K, Matsubara Y, Lim LA, Shimizu E, Yamaguchi R, Yotusuyanagi H, Imoto S, Miyano S, Tojo A.
-
Prognostic impact of circulating tumor DNA status post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Blood. 133(25): 2682-95. 2019
Nakamura S, Yokoyama K, Yusa N, Ogawa M, Takei T, Kobayashi A, Ito M, Jimbo K, Tanoue S, Isobe M, Konuma T, Kato S, Shimizu E, Kasajima R, Wada Y, Yamaguchi R, Imoto S, Nagamura-Inoue T, Takahashi S, Miyano S, Tojo A.
-
Cell lineage-level targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes. Blood Adv. 2(19): 2513-21, 2018
Yokoyama K, Shimizu E, Yokoyama N, Nakamura S, Kasajima R, Ogawa M, Takei T, Ito M, Kobayashi A, Yamaguchi R, Imoto S, Miyano S, Tojo A.
-
Clinical impact of pre-transplant use of multiple tyrosine kinase inhibitors on the outcome of allo-HSCT for CML. Am J Hematol. 92(9):902-8, 2017
Kondo T, Nagamura-Inoue T, Tojo A, Namgamura F, Uchida N, Nakamae H, Fukuda T, Mori T, Yano S, Kurokawa M, Ueno H, Kanamori H, Hashimoto H, Onizuka M, Takanashi M, Ichinohe T, Atsuta Y, Ohashi K; JSHCT adult CML/MPN Working Group.
-
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study. Int J Hematol. 106(3):385-97, 2017
Tojo A, Kyo T, Yamamoto K, Nakamae K, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan, Lustgarten S, Farin H, Haluska F, Ohyashiki K.
-
Cancer progression by reprogrammed BCAA metabolism in myeloid leukemia. Nature 545(7655):500-4, 2017
Hattori A, Tsunoda M, Konuma T, Kobayashi M, Nagy T, McSkimming D, Beattie N, Kannan N, Tojo A, Edison A, Ito T.
-
BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis. Blood. 124(16):2610-1, 2014
Kobayashi M, Tojo A.
-
Effect of graft sources on allogeneic hematopoietic stem-cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis. Int J Hematol. 100(3):296-306, 2014
Ohashi K, Nagamura-Inoue T, Nagamura F, Tojo A, Miyamura K, Ishikawa J, Morishima Y, Mori T, Atsuta Y, Sakamaki H, on behalf of Choric Myeloid Leukaemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
-
In vivo leukemogenic potential of an interleukin-7 receptor- mutant in hematopoietic stem/progenitor cells. Blood. 122(26):4259-63, 2013
Yokoyama K, Yokoyama N, Izawa K, Kotani A, Harashima A, Hozumi K, Tojo A.
-
Therapeutic outcome of multifocal Langerhans cell histiocytosis in adults treated with the Special C regimen formulated by the Japan LCH Study Group. Int J Hematol. 97(1):103-8, 2013
Morimoto A, Shimazaki C, Takahashi S, Yoshikawa K, Nishimura R, Wakita H, Kobayashi Y, Kanegane H, Tojo A, Imamura T, Imashuku S; Japan LCH Study Group.
-
Eltrombopag in refractory aplastic anemia. New Engl J Med. 367:1162-3, 2012
Oshima Y, Yuji K, Tojo A.
-
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study. Int J Hematol. 95:409-19, 2012
Usuki K, Tojo A, Maeda Y, Kobayashi Y, Matsuda A, Ohyashiki K, Nakaseko C, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Okamoto S, Oritani K, Okada M, Usui N, Nagai T, Amagasaki T, Wanajo A, Naoe T.
-
Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 34:1459-71, 2010
Kim DW, Banavali SD, Bunworasate U, Goh YT, Ganly P, Huang H, Irving I, Jootar S, Goh HG, Koh LP, Li W, Naoe T, Ng SC, Purushotaman V, Reksodiputro H, Shih LY, Tang JL, Tojo A, Wang J, Wong R.
-
JTE-607, a multiple cytokine production inhibitor, induces apoptosis accompanied by an increase in p21waf1/cip1 in acute myelogenous leukemia cells. Cancer Sci. 101:774-81, 2010
Tajima N, Fukui K, Uesato N, Maruhashi J, Yoshida T, Watanabe Y, Tojo A.
-
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or –intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol. 89: 679 -88, 2009
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, Ishikawa J, Okada M, Usui N, Tanii H, Amagasaki T, Natori H, Naoe T.
-
Cytogenetic remissions induced by interferon alpha and imatinib mesylate are immunologically distinct in chronic myeloid leukemia. Int J Hematol. 86:208-11, 2007
Nakayama S, Nagamura-Inoue T, Yokoyama K, Ohno N, Ooi J, Takahashi S, Uchimaru K, Iseki T, Tojo A.
-
Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem cell transplantation from related donors in adult patients with hematological malignancies after myeloablative conditioning regimen. Blood. 109:1322-30. 2007
Takahashi S, Ooi J, Tomonari A, Konuma T, Tsukada N, Oiwa-Monna M, Fukuno K, Uchiyama M, Takasugi K, Iseki T, Tojo A, Yamaguchi T, Asano S.
-
JTE-607, a multiple cytokine production inhibitor, ameliorates disease in a SCID mouse xenograft acute myeloid leukemia model. Exp Hematol. 34:1386-92, 2006
Uesato N, Fukui K, Maruhashi J, Tajima N, Tojo A, Watanabe Y.
-
CD34+CD7+ leukemic progenitor cells may be involved in maintenance and clonal evolution of chronic myeloid leukemia. Clin Cancer Res. 11:505-11, 2005
Kosugi N, Ebihara Y, Nakahata T, Saisho H, Asano S, Tojo A.
-
Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematological malignancies. Blood. 104:3813-20, 2004
Takahashi S, Iseki T, Ooi J, Tomonari A, Takasugi K, Shimohakamada Y, Yamada T, Uchimaru K, Tojo A, Shirafuji N, Kodo H, Tani K, Takahashi T, Yamaguchi T, Asano S.
-
CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood. 104:1442-9, 2004
Harata M, Soda Y, Tani K, Ooi J, Takizawa T, Chen M, Bai Y, Izawa K, Kobayashi S, Tomonari A, Nagamura F, Takahashi S, Uchimaru K, Iseki T, Tsuji T, Takahashi TA, Sugita K, Nakazawa S, Tojo A, Maruyama K, Asano S.
-
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 104:356-63, 2004
Soda Y, Tani K, Bai Y, Saiki M, Chen M, Izawa K, Kobayashi S, Takahashi S, Uchimaru K, Kuwabara T, Warashina M, Tanabe T, Miyoshi H, Sugita K, Nakazawa S, Tojo A, Taira K, Asano S.
-
Severe immune dysfunction after lethal neutron irradiation in a JCO nuclear facility accident victim. Int J Hematol. 70:157-64, 2002
Nagayama H, Ooi J, Tomonari A, Iseki T, Tojo A, Tani K, Takahashi AT, Yamashita N, Asano S.
